VIP Peptide for CIRS: The Vasoactive Intestinal Peptide Protocol

At a Glance

Vasoactive intestinal peptide sits at the apex of the Chronic Inflammatory Response Syndrome (CIRS) treatment ladder — used only after biotoxin exposure has been removed, binder therapy completed, and upstream inflammatory markers brought under control. For patients who have done everything right yet still suffer from fatigue, cognitive difficulty, and hormonal dysregulation, a deficiency in endogenous VIP may explain the persistent symptoms. Whether replacing it reliably helps is a question the uncontrolled evidence cannot yet answer.

What VIP Does in the Body

VIP is a 28-amino-acid neuropeptide produced primarily by neurons of the enteric, peripheral, and central nervous systems. It binds VPAC1 and VPAC2 receptors, which are expressed broadly across immune, pulmonary, gut, and neuroendocrine tissues. Its core actions include:

• Anti-inflammatory signalling: VIP suppresses TNF-α, IL-6, and IL-12 production by macrophages and dendritic cells while upregulating IL-10. In CIRS patients, systemic innate immune activation chronically suppresses VIP synthesis.
• MSH regulation: VIP stimulates melanocyte-stimulating hormone (MSH) release from the hypothalamus. Deficient VIP is therefore one of the most common proximal causes of low MSH — a biomarker implicated in sleep disruption, mucosal defence failures, and chronic pain in CIRS.
• Pulmonary vasodilatation: VIP relaxes smooth muscle in pulmonary vasculature. Its deficiency partially explains the pulmonary arterial pressure abnormalities documented in a subset of CIRS patients.
• Hypothalamic–pituitary axis support: VIP modulates ADH, ACTH, and prolactin release. Low VIP correlates with ADH/osmolality dysregulation and MMP-9 elevation — both markers used in Shoemaker-protocol laboratory panels.
• Circadian and autonomic tone: VIP is the primary neuropeptide driving circadian oscillation in the suprachiasmatic nucleus. VIP deficiency contributes to the non-restorative sleep reported by most CIRS patients.

Why CIRS Depletes VIP

In genetically susceptible individuals (HLA-DR haplotypes that cannot clear biotoxins), ongoing exposure to water-damaged building (WDB) organisms — including Aspergillus, Stachybotrys, actinobacteria, and their fragments — triggers a self-perpetuating innate immune activation that bypasses adaptive immune resolution. The resulting cytokine cascade suppresses hypothalamic VIP production through several mechanisms:

1. TGF-β1 elevation directly inhibits VIP synthesis in hypothalamic neurons.
2. Elevated MMP-9 cleaves extracellular matrix and amplifies neuroinflammation, further impairing VIP secretion.
3. VEGF suppression reduces angiogenic support in the VIP-producing hypothalamic circuits.
4. Low MSH creates a feedback loop: since VIP and MSH mutually stimulate each other, once either falls, both decline.

The result is a patient who has left the building, completed binder therapy, and normalised several markers, but whose hypothalamic–pituitary signalling remains dysregulated because VIP never recovered on its own.

The Shoemaker VIP Protocol: Eligibility First

VIP nasal spray is a compounded, unapproved preparation, not a general wellness peptide. The Shoemaker protocol, which is a practitioner protocol rather than an approved treatment pathway, specifies strict eligibility gates:

Required Before Initiating VIP

1. No ongoing mold or biotoxin exposure. ERMI (Environmental Relative Moldiness Index) of the home must be ≤ 2, or the patient must be living in a confirmed-clean environment. Administering VIP into an actively contaminated environment is contraindicated — VIP will not persist and symptoms may worsen.
2. MMP-9 < 332 ng/mL. Elevated MMP-9 indicates active neuroinflammation. VIP given before MMP-9 is controlled may upregulate transforming growth factor pathways in a counterproductive direction.
3. Completed prior protocol steps. The earlier steps of the Shoemaker sequence (cholestyramine or other binder, eradicating nasal colonisers (MARCONS), correcting ADH/osmolality, correcting ACTH/cortisol, addressing androgen deficiency, addressing MMP-9, then addressing VEGF) must be substantially complete.
4. No active MARCONS. Multiply antibiotic-resistant coagulase-negative staphylococci in the nasal passage will re-suppress VIP. MARCONS eradication (typically BEG spray; bismuth, EDTA, gentamicin) is prerequisite.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

The standard protocol uses compounded intranasal VIP spray at 50 mcg per actuation, four times daily (breakfast, lunch, dinner, and bedtime). Most prescriptions are dispensed as a preservative-free formulation in a metered nasal spray device. Treatment duration varies; some patients use VIP continuously for months, others achieve stable remission after a single 3-to-6-month course.

Oral and injectable VIP formulations exist but are not used in CIRS protocols — the intranasal route achieves CNS and local mucosal delivery that parenteral routes do not replicate for this indication.

This dosing comes from Shoemaker’s practitioner protocol and case series; intranasal VIP is not approved by the FDA or EMA for CIRS or any other indication.

Protocol table

Why the doses cannot be compared across uses. The CIRS spray delivers micrograms to the nasal mucosa. The COVID-19 trials gave weight-based IV infusions in an intensive care setting, and the erectile dysfunction product is a local injection combined with phentolamine. Each route has its own dose range, and none of them translates into the others.

Titration as it is actually done. The published CIRS protocol starts with a supervised test spray, then one spray four times daily for a month, stepping up to two sprays four times daily if symptoms persist. In practice, patients who flush, feel faint or feel worse often start at a lower frequency or a diluted spray and take weeks to months to reach the full dose. Normal lipase before starting is a protocol requirement, and practitioner write-ups describe rechecking fasting lipase after the first use, at two weeks and after each dose increase (Dorninger 2025).

What happens after stopping. In the 18-month open-label cohort, five of 20 patients stopped VIP once their symptoms were corrected and did not relapse; most kept using it at some frequency. VIP and MSH levels roughly doubled but stayed below control values even at 18 months (Shoemaker 2013). There are no controlled data on relapse after stopping.

What to Expect Clinically

The following pattern comes from Shoemaker’s uncontrolled case series, not from placebo-controlled trials. In those reports, patients who were exposure-free, MARCONS-negative, and MMP-9 controlled described a stepwise improvement across several domains:

Weeks 1–4: Improved sleep architecture (less non-restorative sleep), mild reduction in cognitive fog, stabilisation of mood.

Weeks 4–8: MSH and VIP levels start to rise, improvement in mucosal defences (fewer recurrent sinusitis or respiratory infections), reduction in pain amplification. In the 18-month series, MSH and VIP rose but stayed significantly below control values throughout (Shoemaker 2013).

Weeks 8–16: Resolution of exercise intolerance in many patients, pulmonary function improvement in those with small airways abnormalities. The 2013 series reported VEGF correcting; in the 2016 series VEGF did not change (Ryan and Shoemaker 2016).

Patients with raised pulmonary artery systolic pressure on stress echocardiography (CIRS can drive measurable pulmonary vascular changes) returned to normal exercise values with VIP in the 2013 series.

Response Predictors

Patients with measurably low VIP on serum testing, verified exposure elimination, and low-normal MMP-9 at baseline show the strongest responses. Partial responders often have occult ongoing exposure (car, workplace, HVAC), persistent MARCONS not detected on initial culture, or concurrent mast cell activation syndrome requiring separate treatment.

What people report: what works and what doesn’t

Sources: the published open-label CIRS series (Shoemaker 2013, 20 patients; Ryan and Shoemaker 2016, 14 patients; Shoemaker et al. 2017, 35 patients), none of which is indexed in PubMed, and patient threads on Reddit’s r/CIRS (1, 2, 3, 4, 5, 6, 7, 8). Much of the CIRS discussion happens in closed Facebook groups that cannot be linked. Patterns, not proof.

Reported to work

• Clearer thinking and better concentration, often the first change people notice, sometimes within days of reaching the full dose of one spray four times daily, in people who had completed the earlier protocol steps.
• Fewer symptoms overall. In the 2016 series, the mean number of CIRS symptoms fell from 12.9 to 3.3 over a mean of 6 months of use, with significant falls in TGF-beta1 and C4a. MMP-9 fell but not significantly, and VEGF did not change.
• Labs moving in the expected direction, including VIP and MSH rising toward the reference range.

Mixed or unclear

• Gut symptoms. Several people describe their cognition improving while digestive symptoms stay the same.
• Labs improving without feeling better. One user describes VIP and MSH reaching or approaching normal after a year with no felt difference.
• Ongoing exposure. People who started VIP while still exposed, or before clearing nasal MARCoNS, often describe reacting badly and then tolerating the same dose later. This fits the protocol’s insistence on exposure removal first, but it is self-reported.
• Starting dose. Some tolerate the standard dose from day one; others need heavily diluted spray and months of slow build-up.

Reported not to work, or disappointing

• No benefit at all in a share of users, including some who used it for many months.
• Feeling worse in the first weeks: anxiety, feeling wired, irritability, low mood, bloating, flu-like symptoms and fatigue.
• Blood pressure effects: light-headedness and faintness, and in one detailed report a marked blood pressure drop with hot and cold flashes and tremor about an hour after the dose.
• Cost and access. One patient reports paying over $400 per bottle, and in the 2017 series 4 of 35 patients could not obtain VIP because of state pharmacy rules.
• Starting too early. Patients given VIP before completing the earlier steps describe it as expensive and ineffective, with side effects.

What a properly designed trial would need to show: a randomised, placebo-controlled trial of intranasal VIP in patients who meet a CIRS case definition and have completed exposure removal, with blinded symptom and cognitive assessment, prespecified biomarkers (TGF-beta1, C4a, MMP-9), safety labs including lipase, and follow-up after stopping. The 2013 paper states that a double-blind, placebo-controlled trial had begun; a PubMed search finds no published results.

Laboratory Monitoring During VIP Therapy

The Shoemaker protocol uses a defined set of biomarkers to titrate and confirm VIP response:

An initial panel at baseline, a repeat at 4–6 weeks, and a final confirmatory panel at 12–16 weeks is a reasonable monitoring schedule. VIP itself should be measured because a subset of patients have poor mucosal absorption and require dose adjustment.

Safety Considerations

Compounded intranasal VIP is reported in case series to be generally well tolerated at 50 mcg four times daily, though systematic safety data are lacking. The most commonly reported adverse effects are:

• Local nasal irritation: transient stinging or congestion, particularly with preservative-containing formulations. A preservative-free base resolves this in most cases.
• Flushing and hypotension: VIP is a potent vasodilator. Patients with baseline hypotension (common in dysautonomic CIRS) should start at lower frequency (twice daily) and titrate up.
• Paradoxical symptom flare in early treatment: thought to reflect immune redistribution. Temporary, typically resolving within 1–2 weeks.

VIP nasal spray should not be initiated in:

• Patients with active mold/biotoxin re-exposure
• Uncontrolled MARCONS nasal colonisation
• MMP-9 > 332 ng/mL
• Active malignancy (VIP receptors are expressed on some tumour cells; theoretical concern without clinical case series confirming risk, but caution is warranted)
• Pregnancy and lactation (insufficient data)

VIP in Broader Context: CIRS Beyond Mold

While the VIP nasal spray protocol was developed and validated primarily in water-damaged building CIRS, VIP deficiency is not exclusive to mold. The same hypothalamic suppression occurs in:

• Post-COVID illness: a distinct but overlapping biotoxin-like inflammatory pattern where VIP levels are suppressed and associated with exercise intolerance and autonomic dysfunction.
• Lyme disease-associated CIRS: chronic neuroborreliosis generates an inflammatory milieu that can exhaust the VIP-MSH axis similarly to mold CIRS.
• Ciguatera toxin CIRS: the marine biotoxin mechanism follows the Shoemaker paradigm, and VIP is similarly depleted.

Outside water-damaged building CIRS, the evidence for VIP replacement is thinner still, and these extensions remain hypotheses.

Related Articles

• CIRS Symptoms: How to Recognise Chronic Inflammatory Response Syndrome
• CIRS vs MCAS: Overlapping but Distinct Conditions
• Mold Illness and CIRS: The Complete Treatment Protocol
• Mold and CIRS Testing: What to Order
• Thymosin Alpha-1: Immune Modulation in Chronic Illness